TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04556877

Intervention type: PROCEDURE
Intervention: Intraabdominal pressure and optic nerve diameters
Description: Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
Study: NCT00304070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Patients undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT04556877

Intervention type: PROCEDURE
Intervention: Intraabdominal pressure and optic nerve diameters
Description: Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG

Intervention type: PROCEDURE
Intervention: Intraabdominal pressure and optic nerve diameters
Description: Measuring Intraabdominal pressure with a Foley cathater and measuring optic nerve diameters with a USG
Study: NCT00304070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given subcutaneously
Study: NCT01049880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with escalating ascorbic acid
Description: Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL.
Study: NCT01542112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSactive model
Description: The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patients in this arm receive the usual routine in the department.
Study: NCT00575588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: open-label metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: open-label metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylurea
Description: Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin 5 mg tablets
Study: NCT05212636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
Study: NCT03525834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
Study: NCT01375296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: China-made SES (Firebird 2 and Excel)
Description: patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).

Intervention type: OTHER
Group type: OTHER
Intervention: routine medicine
Description: patients with coronary 50-70% narrowing treated with routine medicine
Study: NCT03367533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Intravenous ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral perampanel (6 mg)
Study: NCT02618772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
Study: NCT02555254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Speed of Rewarming
Description: Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Speed of Rewarming
Description: Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
Study: NCT03367533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT01913444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Antithrombin
Study: NCT02412345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Study: NCT04461626

Intervention type: DEVICE
Intervention: Persona fixed bearing knee system (All patients will receive Persona fixed bearing knee system)
Study: NCT02691858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Study: NCT01202838

Intervention type: DEVICE
Intervention: Composite Implant
Description: Subjects receiving composite implants
Study: NCT03206021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Azacytidine
Description: Dose escalation of carboplatin combined with 5'azacytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Azacytidine
Description: Dose escalation of carboplatin combined with 5'azacytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Azacytidine
Description: Dose escalation of carboplatin combined with 5'azacytidine
Study: NCT03054909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803 Subcutaneous
Description: Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803 Intraperitoneal
Description: Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
Study: NCT01412424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide capsules
Description: Octreotide was provided in hard gelatin capsules.
Study: NCT04614428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RESILIENCE Program
Description: In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective.
Study: NCT00962429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipoic acid
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lipoic acid
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Study: NCT05634265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vijana-SMART
Description: The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
Study: NCT01970332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Study: NCT03327480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthosis
Description: Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
Study: NCT02412345

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy - sham treatment
Description: A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil
Description: Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
Study: NCT04574622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
Study: NCT03860389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
Study: NCT02897843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS
Study: NCT01405157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 16 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 16 mg single dose
Study: NCT03606161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Undergo nrTMS
Study: NCT03834194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Monthly Weight
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.
Study: NCT06701383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Pulmonary vein isolation using cryoablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Pulmonary vein isolation using cryoablation
Study: NCT06701162

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasoud-guided TAP block
Description: the ultrasound probe was placed at the mid-axillary line, and the needle was inserted into the space between the internal oblique and transverse muscles, splitting the inter-muscular fascia after injection of local anesthetic.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound-guided Ilio-inguinal Ilio-Hypogatric block
Description: the ultrasound probe was positioned transversely on the abdominal wall at the contact point of the anterosuperior iliac spine. The needle was inserted into the space between the internal oblique and transverse muscles, causing separation of the intermuscular fascia layers upon injection of the anesthetic mixture
Study: NCT06701448

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: robotic bronchosopy
Description: robotic bronchoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electromagnetic Navigation Bronchoscopy
Description: Electromagnetic Navigation Bronchoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluoroscopy bronchoscopy
Description: Fluoroscopy bronchoscopy
Study: NCT06700941

Intervention type: BIOLOGICAL
Intervention: HPV vaccine
Description: The intervention of interest in this observational study is the HPV vaccine, which was introduced as part of Colombia's national immunization program in 2012. The vaccine is administered to girls between the ages of 9 and 17 to prevent cervical cancer, preneoplastic cervical lesions, and genital warts caused by HPV infection. The vaccine schedule typically includes two doses given over six months.~This study does not involve administering the vaccine as part of the research. Instead, it retrospectively analyzes the healthcare records of individuals who received the vaccine as part of routine care and compares outcomes with those who were not vaccinated.
Study: NCT03086642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL. The second injection up to 4.0 mL of 10\^6, 10\^7, or 10\^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion.
Study: NCT03834194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Overall Weight + Exercise
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Overall Weight
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Overall Weight
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Overall Weight + Exercise
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery + Monthly Weight + Exercise
Description: Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Monthly Weight
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss + Monthly Weight + Exercise
Description: Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists.
Study: NCT02515019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index Monitoring
Description: In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
Study: NCT01590914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fed Condition
Description: Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasted Condition
Description: Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasted Condition
Description: Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasted Condition
Description: Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasted Condition
Description: Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
Study: NCT03610490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02412345

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil
Description: Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
Study: NCT01430416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study: NCT04731428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercise
Description: Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
Study: NCT04824456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral sagittal split osteotomy using separators.
Description: The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.